Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17136189 | TAU-BINDING ANTIBODIES | December 2020 | April 2023 | Allow | 27 | 1 | 0 | No | No |
| 17136440 | TAU-BINDING ANTIBODIES | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17130477 | BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE | December 2020 | July 2023 | Allow | 31 | 2 | 0 | No | No |
| 17128110 | B-CELL EPITOPE OF TRICHINELLA SPIRALIS CYSTEINE PROTEASE INHIBITOR, HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY AND USES THEREOF | December 2020 | December 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 17126677 | ANTIBODY FOR SKEWING SEX RATIO AND METHODS OF USE THEREOF | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17125172 | METHODS FOR IMPROVING DRUG EFFICACY | December 2020 | January 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17122325 | HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME | December 2020 | April 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17110969 | ANTI-TAU ANTIBODIES AND METHODS OF USE | December 2020 | September 2022 | Allow | 21 | 0 | 0 | No | No |
| 17109604 | ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN | December 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17059268 | ANTI-THYROID HORMONE (T4) RECOMBINANT ANTIBODY OR ANTIGEN BINDING FRAGMENT | November 2020 | October 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 17056816 | BIOPHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODY VARIANTS | November 2020 | November 2022 | Allow | 24 | 1 | 0 | No | No |
| 17098970 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE | November 2020 | March 2023 | Allow | 28 | 1 | 0 | No | No |
| 17097592 | COMPOSITION CONTAINING PORIA COCOS PEEL EXTRACT FOR TREATING NEURODEGENERATIVE DISORDERS | November 2020 | January 2023 | Abandon | 26 | 1 | 0 | Yes | No |
| 17093541 | ANTIBODY BINDING A LINEAR EPITOPE OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOF | November 2020 | August 2021 | Allow | 10 | 2 | 0 | Yes | No |
| 17093527 | ANTIBODY BINDING A LINEAR EPITOPE OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOF | November 2020 | August 2021 | Allow | 9 | 2 | 0 | No | No |
| 17090359 | Immunological Targeting of Pathological Tau Proteins | November 2020 | June 2023 | Allow | 31 | 1 | 1 | No | No |
| 17089599 | ANTIBODIES RECOGNIZING TAU | November 2020 | December 2023 | Abandon | 37 | 2 | 1 | No | No |
| 17089416 | ANTIBODIES RECOGNIZING TAU | November 2020 | October 2022 | Allow | 23 | 1 | 0 | No | No |
| 17088307 | AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY | November 2020 | August 2022 | Allow | 21 | 1 | 0 | No | No |
| 17050947 | ANTIBODY DIRECTED AGAINST A TAU-DERIVED NEUROTOXIC PEPTIDE AND USES THEREOF | October 2020 | September 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17050056 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN | October 2020 | December 2022 | Allow | 25 | 2 | 0 | No | No |
| 17050072 | SERUM ALBUMIN BINDING ANTIBODIES FOR TUNEABLE HALF-LIFE EXTENSION OF BIOLOGICS | October 2020 | April 2022 | Allow | 18 | 1 | 0 | Yes | No |
| 17076772 | TREATING REFRACTORY MIGRAINE | October 2020 | March 2021 | Allow | 5 | 1 | 0 | No | No |
| 17076759 | TREATING REFRACTORY MIGRAINE | October 2020 | March 2021 | Allow | 5 | 1 | 0 | No | No |
| 17046551 | ANTIBODIES AGAINST BST1 FOR PREVENTING OR TREATING MYELODYSPLASTIC SYNDROME | October 2020 | December 2022 | Abandon | 26 | 2 | 0 | No | No |
| 17067100 | ANTI-TAU ANTIBODIES AND METHODS OF USE | October 2020 | February 2022 | Allow | 16 | 1 | 0 | No | No |
| 17021042 | ANTI-SARS-COV-2 ANTIBODIES AND APPLICATION THEREOF | September 2020 | January 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17017685 | SYSTEMS AND METHODS FOR THE PREPARATION OF PEPTIDE-MHC-I COMPLEXES WITH NATIVE GLYCAN MODIFICATIONS | September 2020 | December 2023 | Abandon | 39 | 1 | 1 | No | No |
| 17004447 | AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY | August 2020 | January 2022 | Allow | 17 | 0 | 0 | Yes | No |
| 16975120 | CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONIST ANTIBODIES | August 2020 | October 2022 | Allow | 26 | 1 | 0 | No | No |
| 16998291 | THERAPEUTIC ANTIBODIES FOR TREATMENT OF NEURODEGENERATION | August 2020 | April 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16986615 | Anti-PHF-Tau Antibodies and Uses Thereof | August 2020 | February 2022 | Allow | 18 | 1 | 0 | No | No |
| 16985780 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | August 2020 | March 2022 | Allow | 19 | 2 | 1 | No | No |
| 16943123 | ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF | July 2020 | January 2023 | Allow | 30 | 2 | 0 | Yes | No |
| 16965271 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS | July 2020 | July 2022 | Allow | 24 | 2 | 0 | No | No |
| 16961737 | FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF | July 2020 | February 2022 | Allow | 20 | 2 | 0 | No | No |
| 16926062 | HUMANIZED TAU ANTIBODIES IN ALZHEIMER'S DISEASE | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16959385 | MISFOLDED TDP-43 BINDING MOLECULES | June 2020 | May 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16909398 | Novel Anti-Human Transferrin Receptor Antibody Capable of Penetrating Blood-Brain Barrier | June 2020 | March 2021 | Allow | 9 | 1 | 0 | Yes | No |
| 16955644 | PURIFIED ARYLSULFATASE A AND COMPOSITONS THEREOF | June 2020 | December 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16903271 | Humanized Antibodies That Recognize Alpha-Synuclein | June 2020 | January 2022 | Allow | 19 | 1 | 0 | No | No |
| 16954483 | ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE | June 2020 | February 2023 | Allow | 32 | 1 | 1 | No | No |
| 16899307 | MONOCLONAL ANTIBODIES TARGETING PHF1 AND AT8 EPITOPES OF HUMAN TAU PROTEIN | June 2020 | May 2022 | Allow | 24 | 2 | 0 | Yes | No |
| 16772043 | ANTI-ALPHA SYNUCLEIN ANTIBODIES | June 2020 | December 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16771993 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES | June 2020 | November 2021 | Allow | 17 | 1 | 0 | No | No |
| 16895471 | AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY | June 2020 | August 2022 | Allow | 26 | 1 | 0 | No | No |
| 16893678 | ANTI-TAU ANTIBODIES AND METHODS OF USE | June 2020 | March 2022 | Allow | 22 | 1 | 0 | No | No |
| 16768091 | CELL CULTURE METHODS | May 2020 | May 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16768429 | POLYOMAVIRUS NEUTRALIZING ANTIBODIES | May 2020 | April 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16767152 | Compositions and Methods for Cancer Therapy | May 2020 | February 2022 | Allow | 21 | 1 | 1 | No | No |
| 16883515 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | May 2020 | March 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16880431 | METHODS OF NEUROPROTECTION INVOLVING MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR AGONISTS | May 2020 | August 2022 | Abandon | 27 | 4 | 0 | No | No |
| 16874019 | CAVEOLIN-1 ANTIBODY FOR USE IN TREATING BRAIN INFLAMMATION AND INJURY AND IMPROVING FUNCTIONAL RECOVERY | May 2020 | July 2021 | Allow | 14 | 2 | 0 | Yes | No |
| 16763906 | USE OF SRSF3 AGENTS FOR THE TREATMENT AND/OR PREVENTION OF NEUROLOGICAL CONDITIONS, CANCER, BACTERIAL INFECTIONS OR VIRAL INFECTIONS | May 2020 | August 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16867324 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, AND OTHER DISORDERS | May 2020 | March 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16760487 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | April 2020 | February 2022 | Abandon | 21 | 2 | 0 | No | No |
| 16857636 | TARGETING G3BP PROTEINS TO ACCELERATE NERVE REGENERATION | April 2020 | November 2021 | Abandon | 19 | 2 | 0 | No | No |
| 16852182 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING PARKINSON'S DISEASE COMPRISING STT AS AN ACTIVE INGREDIENT | April 2020 | August 2022 | Allow | 28 | 1 | 0 | No | No |
| 16849515 | PROTEIN-INDUCED PLURIPOTENT CELL TECHNOLOGY AND USES THEREOF | April 2020 | February 2023 | Allow | 34 | 1 | 0 | No | No |
| 16755461 | METHODS OF INDUCING COMPLEMENT ACTIVITY | April 2020 | August 2021 | Allow | 16 | 1 | 0 | No | No |
| 16754954 | PRODUCTS AND METHODS ASSOCIATED WITH MULTIPLE SCLEROSIS AS A TRANSMISSIBLE PROTEIN MISFOLDING DISORDER | April 2020 | February 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16754576 | ANTI AQP3 MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF | April 2020 | January 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 16842073 | METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED CONDITIONS | April 2020 | April 2021 | Allow | 12 | 2 | 0 | No | No |
| 16753307 | ANTI-TRANSTHYRETIN ANTIBODIES | April 2020 | October 2021 | Allow | 19 | 1 | 1 | Yes | No |
| 16838235 | ANTI-TAUC3 ANTIBODIES AND USES THEREOF | April 2020 | June 2021 | Allow | 15 | 1 | 0 | No | No |
| 16820639 | COMPOSITION CONTAINING MIXED EXTRACT OF MULBERRY AND PORIA COCOS BARK FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERS | March 2020 | November 2020 | Allow | 8 | 1 | 0 | No | No |
| 16820269 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | March 2020 | August 2022 | Allow | 29 | 1 | 0 | Yes | No |
| 16644695 | METHODS FOR DETECTION OF FOLATE RECEPTOR 1 IN A PATIENT SAMPLE | March 2020 | June 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16810667 | TREATMENT OF DAMAGED NERVE WITH PTEN INHIBITOR | March 2020 | March 2022 | Abandon | 24 | 2 | 0 | No | Yes |
| 16789626 | ANTIBODIES COMPRISING A COMMON LIGHT CHAIN AND USES THEREOF | February 2020 | October 2021 | Allow | 20 | 1 | 0 | No | No |
| 16639050 | NOVEL NICOTINE-BINDING ANTIBODIES | February 2020 | May 2022 | Allow | 27 | 0 | 0 | Yes | No |
| 16790066 | CLAUDIN 6 ANTIBODIES AND USES THEREOF | February 2020 | October 2021 | Allow | 20 | 1 | 0 | No | No |
| 16788851 | ELECTROACTIVE POLYMERIC SCAFFOLDS AND METHOD FOR DELIVERING NERVE GROWTH FACTOR TO NERVE TISSUE | February 2020 | March 2022 | Allow | 25 | 2 | 0 | No | Yes |
| 16637567 | TAU AGGREGATION PEPTIDE INHIBITORS | February 2020 | June 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16782984 | AFFINITY-BASED METHODS FOR USING TRANSFERRIN RECEPTOR-BINDING PROTEINS | February 2020 | April 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16635796 | IMPROVED HUMAN �2-GLYCOPROTEIN I EXPRESSION | January 2020 | January 2023 | Allow | 36 | 2 | 0 | No | No |
| 16777290 | CHLOROGENIC ACID COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | January 2020 | January 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16751886 | ASSAYS TO DETECT NEURODEGENERATION | January 2020 | December 2020 | Allow | 10 | 2 | 0 | No | No |
| 16633741 | METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS | January 2020 | September 2022 | Abandon | 31 | 3 | 1 | No | No |
| 16751120 | ANG (1-7) DERIVATIVE OLIGOPEPTIDES AND METHODS FOR USING AND PRODUCING THE SAME | January 2020 | May 2021 | Allow | 16 | 2 | 0 | No | No |
| 16751187 | STABLE COMPOSITIONS OF NEUROACTIVE PEPTIDES | January 2020 | October 2021 | Abandon | 20 | 2 | 0 | No | No |
| 16749185 | Bicyclic Compounds and Methods for Their Use in Treating Autism | January 2020 | October 2021 | Allow | 20 | 2 | 0 | Yes | No |
| 16746725 | HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME | January 2020 | September 2020 | Allow | 8 | 1 | 0 | No | No |
| 16744697 | BISPECIFIC HER2 ANTIBODIES AND METHODS OF USE | January 2020 | February 2023 | Allow | 37 | 1 | 0 | Yes | No |
| 16631400 | TARGETING SYNAPTOGYRIN-3 IN TAUOPATHY TREATMENT | January 2020 | January 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16631360 | SERUM ALBUMIN BINDING AGENTS | January 2020 | June 2021 | Allow | 17 | 1 | 0 | No | No |
| 16630975 | ANTI-CD166 ANTIBODIES AND USES THEREOF | January 2020 | August 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16736316 | FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION | January 2020 | August 2021 | Abandon | 20 | 2 | 0 | No | No |
| 16731648 | REGULATING PROTEIN SPONTANEOUS RUPTURES | December 2019 | November 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16726575 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | December 2019 | September 2020 | Allow | 9 | 1 | 0 | No | No |
| 16626311 | PEDIATRIC OSTEOPOROSIS DRUG THAT DOES NOT CAUSE GROWTH DISORDER | December 2019 | September 2021 | Allow | 21 | 1 | 0 | No | No |
| 16625683 | NEW REAGENTS FOR OPTICAL MICROSCOPY | December 2019 | July 2023 | Allow | 43 | 2 | 0 | No | No |
| 16723143 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | December 2019 | October 2020 | Allow | 10 | 1 | 0 | No | No |
| 16715798 | ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDE | December 2019 | April 2021 | Allow | 16 | 2 | 0 | Yes | No |
| 16623254 | Compositions and Methods for Treating and Preventing Staphylococcus Aureus Infections | December 2019 | October 2023 | Abandon | 46 | 2 | 0 | No | Yes |
| 16712652 | HUMAN ALZHEIMER'S DISEASE AND TRAUMATIC BRAIN INJURY ASSOCIATED TAU VARIANTS AS BIOMARKERS AND METHODS OF USE THEREOF | December 2019 | September 2022 | Allow | 33 | 1 | 1 | No | No |
| 16618864 | NOVEL ANTI-HSA ANTIBODIES | December 2019 | February 2022 | Allow | 26 | 2 | 0 | Yes | No |
| 16616752 | Voltage-Gated Calcium Channel Auxilliary Subunit Alpha 2 Delta and Uses Thereof | November 2019 | September 2023 | Abandon | 45 | 1 | 1 | No | No |
| 16616262 | LIGANDS BINDING TO PRION PROTEIN FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | November 2019 | July 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16686610 | BIOSENSOR FOR DIAGNOSING ALZHEIMER'S DISEASE USING RAYLEIGH SCATTERING AND COLORIMETRIC ASSAY OF GOLD NANOPARTICLE AND MULTI-DETECTION METHOD USING THE BIOSENSOR | November 2019 | December 2021 | Allow | 25 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEIDNER, ADAM M.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WEIDNER, ADAM M works in Art Unit 1649 and has examined 606 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 23 months.
Examiner WEIDNER, ADAM M's allowance rate of 62.5% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WEIDNER, ADAM M receive 1.77 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WEIDNER, ADAM M is 23 months. This places the examiner in the 84% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +43.7% benefit to allowance rate for applications examined by WEIDNER, ADAM M. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.7% of applications are subsequently allowed. This success rate is in the 48% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 48.4% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 69% percentile among all examiners. Of these withdrawals, 92.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 88.3% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.2% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.